INCLUSION COMPLEXATION OF PROPOFOL WITH 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN - PHYSICOCHEMICAL, NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPIC STUDIES, AND ANESTHETIC PROPERTIES IN RAT

Citation
G. Trapani et al., INCLUSION COMPLEXATION OF PROPOFOL WITH 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN - PHYSICOCHEMICAL, NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPIC STUDIES, AND ANESTHETIC PROPERTIES IN RAT, Journal of pharmaceutical sciences, 87(4), 1998, pp. 514-518
Citations number
28
Categorie Soggetti
Chemistry Medicinal","Pharmacology & Pharmacy
ISSN journal
00223549
Volume
87
Issue
4
Year of publication
1998
Pages
514 - 518
Database
ISI
SICI code
0022-3549(1998)87:4<514:ICOPW2>2.0.ZU;2-J
Abstract
An aqueous formulations of propofol 1 can be prepared by solubilizing it in the presence of 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD). This is potentially useful for parenteral administration of the drug. The aqueous solubility of 1 linearly increased as a function of HP-bet a-CD concentration and showed features of an A(L) type diagram. Thermo dynamic parameters were obtained by using the temperature dependence o f the stability constant at temperatures of between 25 and 37 degrees C. The results indicate that complex formation is enthalpically, rathe r than entropically, driven and that it may involve van der Waals (dis persive) forces, rather than hydrophobic interactions. The structure o f the inclusion complex propofol/HP-beta-CD was investigated in D2O, u sing H-1 and C-13 NMR spectroscopy. These studies revealed that the wh ole aromatic ring, as well as part of the isopropyl groups of the gues t molecule, is located inside the HP-beta-CD cavity, while the hydroxy group is located at the rim of the wider cavity end. The geometrical features of the inclusion complex 1-HP-beta-CD are confirmed by 1D NOE difference spectra and molecular modeling experiments. The anesthetic activity in rat was investigated, and it was found that there are sig nificant differences in induction time and sleeping time between 1 sol ubilized in the presence of HP-beta-CD and the formulation currently u sed (Diprivan), which is a 1% w/v oil/water emulsion.